Comparison of iodine-123-iomazenil spect and technetium-99m-HMPAO-SPECT in Alzheimer's disease

Journal of Nuclear Medicine

Volumn 38, Issue 3, 1997, Pages 467-470

  Fukuchi, Kazuki ^a   Hashikawa, Kazuo ^a   Seike, Yujiro ^a   Moriwaki, Hiroshi ^a   Oku, Naohiko ^a   Ishida, Mariko ^a   Fujita, Masahiro ^a   Uehara, Toshiisa ^a   Tanabe, Hirotaka ^a   Kusuoka, Hideo ^a   Nishimura, Tsunehiko ^a  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

Alzheimer's disease; Benzodiazepine receptor; Iodine 123 iomazenil; Technetium 99m HMPAO

Indexed keywords

BENZODIAZEPINE RECEPTOR; HEXAMETHYLPROPYLENE AMINE OXIME TECHNETIUM TC 99M; IOMAZENIL; IOMAZENIL I 123; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ADULT; ALZHEIMER DISEASE; ARTICLE; BRAIN BLOOD FLOW; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; RADIOISOTOPE DISTRIBUTION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ALZHEIMER DISEASE; BRAIN; FEMALE; FLUMAZENIL; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; ORGANOTECHNETIUM COMPOUNDS; OXIMES; TECHNETIUM TC 99M EXAMETAZIME; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0030967717     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Holman BL, Johnson KA, Gerada B, Carvalho PA, Satlin A. The scintigraphic appearance of Alzheimer's disease: A prospective study using technetium-99m-HMPAO-SPECT. J Nucl Med 1992;33:181-185.
2. Cross AJ, Crow TJ, Ferner IN, Johnson JA. The selectivity of the reduction of serotonin S2 receptors in Alzheimer-type dementia. Neurobiol Aging 1985;7:3-7.
3. Griffiths PD, Crossman AR. Receptor changes in the neocortex of postmortem tissue in Parkinson's disease and Alzheimer's disease. Dementia 1992;3:239-246.
4. Beer H, Bläuenstein PA, Hasler PH, et al. In vitro and in vivo evaluation of iodine-123-Ro 16-0154: A new imaging agent for SPECT investigations of benzodiazepine receptors. J Nucl Med 1990;31:1007-1014.
5. 123-I-iomazenil versus HMPAO. AJNR 1992;13:249-253.
6. 18F-FDG-PET and ictal EEG findings in patients with medically intractable complex partial seizures. Acta Neurochir 1990; 50(suppl):95-99.
7. Shimohama S, Taniguchi T, Fujiwara M, Kameyama M. Changes in benzodiazepine receptors in Alzheimer-type dementia. Ann Neurol 1988;23:404-406.
8. Mckhann G, Drachman D, Folsteinal M, Katzman R, Price P, Stadlar EM. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA work group under the auspices of the department of health and human services task force on Alzheimer's disease. Neurology 1984;34:939-944.
9. Kimura K, Hashikawa K, Etani H, et al. A new apparatus for brain imaging: four-head rotating gamma camera single-photon emission computed tomography. J Nucl Med 1990;31:603-609.
10. Schubiger PA, Hasler PH, Beer-Wohlfahrt H, et al. Evaluation of a multicenter study with iomazenil - a benzodiazepine receptor ligand. Eur J Nucl Med 1991;12:569-582.
11. 123I-iomazenil: a new probe to evaluate central-type benzodiazepine receptor with SPECT. Jpn J Nucl Med 1995;32:87-97.
12. Aquiloniws S, Eckerns A. A color atlas of the human brain. New York: Raven Press, 1980.
13. Onishi Y, Yonekura Y, Nishizawa, et al. Noninvasive quantification of iodine-123-iomazenil SPECT. J Nucl Med 1996;37:374-378.
14. 123I] iomazenil in healthy human subjects. Psych Res Neuroimag 1992;45:67-77.
15. Lassen NA, Andersen AR, Friberg L, Paulson OB. The retention of [99mTc]-d,l-HM-PAO in the human brain after intracarotid bolus injection: a kinetic analysis. J Cereb Blood Flow Metab 1988;8:S13-S22.
16. 123I] isopropyliodoamphetamine as a tracer for local cerebral blood flow using direct autoradiographic comparison. J Cereb Blood Flow Metab 1982;2:179-185.
17. Friedland RP, Brun A, Budinger TF. Pathological and positron emission tomographic correlation in Alzheimer's disease. Lancet 1985;1:228.
18. Hendry SHC, Schwark HD, Jones EG, Yan J. Numbers and proportions of GABA-immunoreactive neurons in different areas of monkey cerebral cortex. J Neurosci 1987;7:1503-1519.
19. Laruelle M, Baldwin RM, Rattner Z, et al. SPECT quantification of [123I] iomazenil binding to benzodiazepine receptors in nonhuman primates: I. kinetic modeling of single bolus experiments. J Cereb Blood Flow Metab 1994;14:439-452.
20. Abi-Dargham A, Laruelle M, Seibyl J, et al. SPECT measurement of benzodiazepine receptors in human brain with iodine-123-iomazenil: kinetic and equilibrium paradigms. J Nucl Med 1994;35:228-238.
21. Onishi Y, Yonekura Y, Mukai T, et al. Simple quantification of benzodiazepine receptor binding and ligand transport using iodine-123-iomazenil and two SPECT scans. J Nucl Med 1995;36:1201-1210.
22. 123IQNB and single-photon emission computed tomography. Arch Neurol 1991;48: 169-176.
23. Meyer MA, Koeppe RA, Frey KA, Foster NL, Kuhl DE. Positron emission tomography measures of benzodiazepine binding in Alzheimer's disease. Arch Neurol 1995;52:314-317.
24. 125I-Ro16-0154: potential probe for SPECT brain imaging. Life Sci 1990;47:1535-1546.
25. 123I-iomazenil SPECT. Jpn J Nucl Med 1996;33:191-205.
26. 123I-Iomazenil, a new central-type benzodiazepine receptor imaging agent (part 2): report on clinical usefulness in diagnosis of degenerative neurological diseases and mental disorders. Jpn J Nucl Med 1996;33:303-318.